Bio-Rad Laboratories, Inc. (BIO) is a Medical - Devices company in the Healthcare sector, currently trading at $292.23. It has a SharesGrow Score of 64/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of BIO = $482.80 (+65.2% from the current price, the stock appears undervalued). Analyst consensus target is BIO = $328 (+12.1% upside).
Valuation: BIO trades at a trailing Price-to-Earnings (P/E) of 9.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.79.
Financials: revenue is $2.6B, -2.6%/yr average growth. Net income is $760M, growing at +11.4%/yr. Net profit margin is 29.4% (strong). Gross margin is 52% (-3.9 pp trend).
Balance sheet: total debt is $1.5B against $7.5B equity (Debt-to-Equity (D/E) ratio 0.21, conservative). Current ratio is 5.62 (strong liquidity). Debt-to-assets is 14.5%. Total assets: $10.6B.
Analyst outlook: 8 / 14 analysts rate BIO as buy (57%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 48/100 (Partial), Past 25/100 (Fail), Health 83/100 (Pass), Moat 65/100 (Partial), Future 52/100 (Partial), Income 85/100 (Pass).
